louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01407861: Aerobic Endurance Training vs. Relaxation Training in Patients With Migraine
Official title: Aerobic Endurance Training Versus Relaxation Training in Migraine Prophylaxis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Migraine
Lead sponsor: Universität Duisburg-Essen
Sponsor class: OTHER
First posted: 2011-08-02
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a single centre, open label, prospective, randomized study on the prophylactic effect of moderate aerobic endurance training versus relaxation training in patients with migraine.


Eligibility criteria: Inclusion Criteria:

* Patient's signature on the informed consent document \[each patient should be given ample time to read (or have read to them) the consent form, ask any questions they may have regarding the trial and have a clear understanding of the trial and the procedures involved prior to the signing of the consent form\].
* Patients have a clinical diagnosis of migraine with or without aura according to IHS criteria at least one year prior to enrollment.
* Patients have a clinical diagnosis of migraine with or without aura and in addition a clinical diagnosis of tension type headache according to IHS criteria, if patients are able to differentiate between the two headache diagnoses and if migraine is more frequent in these patients
* Patients that report at least three headache days per month

Exclusion Criteria:

* Diseases or disabilities that disqualify to perform either aerobic endurance training or relaxation training
* Language difficulties that disable to fill out questionnaires
* Pregnancy
* Additional diagnosis of secondary headache according to the IHS criteria

Primary outcomes:
measure: Reduction of headache days in the last 4 weeks of the 12-week training compared to baseline (4 weeks before start of the training).
timeFrame: 16 weeks
Secondary outcomes:
measure: Number of headache days 12 weeks after finishing the training (follow up).
timeFrame: 20 weeks
measure: Consumption of analgetic agents/triptans
timeFrame: 20 weeks
measure: Increase in aerobic capability
timeFrame: 12 weeks
measure: Impact on burden of disease
timeFrame: 20 weeks
measure: Psychological Impact of Training
timeFrame: 20
Other outcomes:
Locations:
city: Essen
country: Germany
facility: Department of Neurology, University of Duisburg-Essen
Study officials:
affiliation: Department of Neurology, University of Duisburg-Essen
name: Charly Gaul, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Totzeck A, Unverzagt S, Bak M, Augst P, Diener HC, Gaul C. Aerobic endurance training versus relaxation training in patients with migraine (ARMIG): study protocol for a randomized controlled trial. Trials. 2012 Apr 27;13:46. doi: 10.1186/1745-6215-13-46.
Clinical trial NCT00899561: Computed Tomography (CT) Score and Histopathology of the Middle Turbinate in Chronic Rhinosinusitis
Official title: Correlation Between Middle Turbinate Histopathology and Computed Tomography Staging in Chronic Rhinosinusitis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Rhinosinusitis
Keywords: Chronic rhinosinusitis
Computed tomography
Histology
Middle turbinate
Morphometry
osteomyelitis
polyps
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
Collaborators: name: Tel-Aviv Sourasky Medical Center
First posted: 2009-05-12
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with a limited (of 1-8), intermediate (9-16), and extensive (17-24) sinus disease.

Brief summary: In a previous study (Berger el al. Old and new aspects of middle turbinate histopathology. Otolaryngol Head Neck Surg. 2009;140:48-54), the investigators reported significant histopathologic changes in the middle turbinate mucosa of patients with chronic rhinosinusitis compared with normal controls. However, patients' mean Lund-MacKay CT score was 6.5±6.7 and were considered as having a relatively limited sinus disease (a score of 1-8). Nine to sixteen was considered as intermediate sinus disease, and 17-24 extensive. No osteomyelitic changes were seen in this study group.

The investigators hypothesize that a comparison between the three groups of patients with chronic rhinosinusitis having limited, intermediate, and extensive sinus disease would show that the higher the CT staging, the greater the histopathologic changes of the middle turbinate. The investigators also expect to find osteomyelitic changes in the middle turbinate of patients with higher CT staging.


Eligibility criteria: Inclusion Criteria:

* Adult patients with chronic rhinosinusitis who failed conservative medical treatment,
* Patients who stopped treatment (topical or systemic corticosteroids) at least two months before endoscopic sinus surgery.

Exclusion Criteria:

* Immunosuppressed patients,
* Patients in whom no indication to excise the middle turbinate was found, AND
* Patients in whom a pathologic evaluation of the middle turbinate was necessary (e.g., suspected neoplastic disorder).

Primary outcomes:
measure: inflammation of soft tissue and bony elements of the middle turbinate
timeFrame: two years
Secondary outcomes:
measure: correlation between middle turbinate histopathology and CT staging in chronic rhinosinusitis
timeFrame: two years
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: Meir Medical Center
city: Kfar Saba
country: Israel
facility: Meir Medical Center
Study officials:
affiliation: Meir Medical Center
name: Gilead Berger, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Tel-Aviv Sourasky Medical Center
name: Roee Landsberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01661361: Optimalisation of Therapeutic Drug Monitoring (TDM) of Vancomycin in Patients With Central Venous Port Devices
Official title: Optimalisation of Therapeutic Drug Monitoring (TDM) of Vancomycin in Patients With Central Venous Port Devices
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Catheter-related Infection
Keywords: vancomycin
levels
central venous port device
peripherally obtained levels
dose adjustments
TDM
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2012-08-09
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients admitted for catheter related infection with methicillin-resistant coagulase-negative staphylococci (MR-CNS) and treated with systemic vancomycin in combination with vancomycin antibiotic lock via central venous port device.

Brief summary: Recently, it was reported that when vancomycin levels are determined after port sampling, levels can be falsely increased potentially leading to wrong dose adjustments.

The investigators conducted an in vitro experiment using several central venous port devices, in which different flushing techniques were evaluated yielding residual vancomycin levels of less than 0.5 mg/L.

In this study, the investigators want to evaluate this flushing technique in vivo in 15 patients admitted with catheter-related infection and treated with systemic vancomycin and vancomycin antibiotic lock.

The purpose is to assess if correct flushing can avoid spurious vancomycin levels obtained via port sampling.


Eligibility criteria: Inclusion Criteria:

* adult patients,
* having central venous port device,
* treated with systemic vancomycin in combination with vancomycin antibiotic lock

Exclusion Criteria:

* pregnant women,
* children,
* patients with 'do not resuscitate' (DNR) code

Primary outcomes:
measure: comparison of central (via port device) and peripherally obtained vancomycin levels: the difference, when using the new flushing technique, is allowed to be maximally 0.5 mg/L
timeFrame: central and peripheral vancomycin levels will be obtained during steady state: this means starting from the 4th dose (= day 2) of vancomycin treatment. Vancomycin is usually given during 14 days after the last positive blood culture.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Pharmacy Dpt, University Hospitals Leuven
name: Isabel Spriet, PharmD PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Medical Diagnostic Sciences, University Hospitals Leuven
name: Jan Verhaegen, MD PhD
role: STUDY_CHAIR
affiliation: Digestive ONcology, University Hosptials Leuven
name: Hans Prenen, MD PhD
role: STUDY_CHAIR
affiliation: Internal Medicine, University Hospitals Leuven
name: Willy Peetermans, MD PhD
role: STUDY_CHAIR
affiliation: Pharmacy Dpt., University Hosptials Leuven
name: Ludo Willems, PharmD PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06749561: A Comparative Investigation of Efficacy and Complications in Light and Deep Chemical Peels
Official title: A Comparative Investigation of Efficacy and Complications in Light and Deep Chemical Peels
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Peeling Skin Syndrome
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2024-12-27
Enrollment: 112
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: To check the outcomes of Efficacy and Complications in Light and Deep Chemical Peels

Brief summary: Chemical peeling involves applying substances to the skin to induce controlled damage, which promotes the regeneration of fresh skin cells and enhances the skin's appearance.

Detailed description: This study will be a cross-sectional analysis with a sample size of 112 patients.

Eligibility criteria: Inclusion Criteria:

* Healthy males and females aged 18-35 years.
* Willing to provide informed consent and follow the treatment protocol.

Exclusion Criteria:

* Pregnant or breastfeeding women.
* Active skin conditions (e.g., acne, eczema).
* Use of medications that affect skin healing.
* Known allergies to chemical peel substances.

Primary outcomes:
measure: Dermatological Assessment Score (DAS)
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Block E3 E-3 Gulberg III
state: Punjab
Study officials:
References:
Clinical trial NCT02217761: Pharmacokinetic Study in Patients Receiving Posaconazole Therapy in Taiwan
Official title: Pharmacokinetic Study in Patients Receiving Posaconazole Therapy in Taiwan
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pharmacokinetics
Posaconazole
Keywords: Pharmacokinetics
Antifungal Agents
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2014-08-15
Enrollment: 400
Sex: ALL
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients in National Taiwan University receiving posaconazole

Brief summary: The purpose of this study is to investigate the factors influencing pharmacokinetic and pharmacodynamic properties of new antifungal agent, posaconazole in Taiwanese patients.

Detailed description: Invasive fungal infection (IFI) may cause high mortality and morbidity in immune- compromised patients. Posaconazole, a new triazole antifungal agent with broad spectrum coverage, was approved for both treatment and prophylaxis of IFIs. Previous studies have demonstrated the relationship between posaconazole plasma concentration and efficacy, thus, the importance of posaconazole therapeutic drug monitoring (TDM) was gradually accepted. However, studies found inter- and intra-individual variation between concentrations, and these phenomenons were affected greatly by GI function, food intake and concomitant medication. Furthermore, there's a lack of posaconazole TDM study in Asian population.

The study was designed to describe the prescribing pattern of posaconazole, to study the relationship between concentration and clinical outcomes/ adverse events, to identify factors that influence plasma concentration, and to evaluate whether routine TDM is needed in our institution.

Eligibility criteria: Inclusion Criteria:

* Patients receiving posaconazole therapy
* Patients aged 13 years old or more

Exclusion Criteria:

* No posaconazole plasma concentration available

Primary outcomes:
measure: Plasma posaconazole concentration
timeFrame: 7-10 days after taking posaconazole
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Graduate institute of clinical pharmacy at National Taiwan University
name: Shu-Wen Lin, Pharm. D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01367561: Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function
Official title: A Phase I Urodynamic Study of the Opioid Antagonist, Naloxone and Intravenous Methylnaltrexone Reverse Opioid Effects on Bladder Function in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Males
Lead sponsor: Bausch Health Americas, Inc.
Sponsor class: INDUSTRY
First posted: 2011-06-07
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a double-blind, randomized, study at a single clinical site investigating the effect of methylnaltrexone and naloxone versus placebo in healthy males who have received a short-acting opioid, remifentanil.


Eligibility criteria: Inclusion Criteria:

1. Healthy males, 18 to 65 yrs with normal urinary function
2. Body weight less than 150 kg and Body Mass Index between 20-32.

Exclusion Criteria:

1. Females
2. History of drug or alcohol abuse
3. History of significant chronic illness (cardiovascular, gastrointestinal, pulmonary, neurologic, endocrine, renal, hepatic, etc.)
4. Subjects who received opioids for one week or longer in the last 2 months.

Primary outcomes:
measure: Maximal force of detrusor contraction (Pdet) after administration of MNTX
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Tarrytown
country: United States
facility: Progenics Pharmaceuticals, Inc.
state: New York
Study officials:
affiliation: Progenics Pharmaceuticals, Inc.
name: Tage Ramakrishna, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05816161: Integrated Neuromuscular Inhibition Technique and Myofascial Release on Cervical Range of Motion and Dysfunction
Official title: Comparison of The Effects of The Integrated Neuromuscular Inhibition Technique and Myofascial Release on Cervical Range of Motion and Dysfunction in Individuals With Nonspecific Cervical Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Myofascial Trigger Point Pain
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2023-04-18
Enrollment: 30
Sex: ALL
Minimum age (years): 25
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: to findout the improvement by Integrated Neuromuscular Inhibition Technique and Myofascial Release on Cervical Range of Motion and Dysfunction


Eligibility criteria: Inclusion Criteria:

* ● Age between 25-40

  * Both males and females included
  * Participants suffering from recent cervical pain without any pathology.

Exclusion Criteria:

* ● Participants having cervical radiculopathy

  * Having recent trauma of the cervical spine
  * Non-cooperative subject

Primary outcomes:
measure: Cervical Range of Motion measurement
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Chaudhary Muhammad Akram Hospital
state: Punjab
Study officials:
References:
Clinical trial NCT01075061: Study of a Large Family With Congenital Mirror Movements : From Underlying Pathophysiology to Culprit Gene Identification PROJET " MOMIC "
Official title: Study of a Large Family With Congenital Mirror Movements : From Underlying Pathophysiology to Culprit Gene Identification : MOMIC
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Congenital mirror movement, physiopathology, imaging, transcranial magnetic stimulation, candidate gene
Lead sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Sponsor class: OTHER_GOV
First posted: 2010-02-24
Enrollment: 40
Sex: ALL
Minimum age (years): 11
Maximum age (years): 82
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Mirror movements are involuntary, symmetrical and simultaneous movements occurring on one side of the body that accompany controlateral voluntary movements. Congenital mirror movements (CMM) are characterized by childhood onset and the absence of additional manifestations. The aim of this study is to unravel the pathophysiology of the CMM that remains poorly elucidated. The combination of imaging studies and neurophysiological studies using transcranial magnetic stimulation in a homogeneous and relatively large group of patient is likely to allow us to better understand the underlying pathophysiology of the disorder. Using a linkage analysis approach we will try to identify a locus associated with CMM and related candidate genes.


Eligibility criteria: Inclusion Criteria:

* Patients aged from 11 to 82 years
* Members of the family of interest displaying mirror movements or being obligatory asymptomatic carrier, without additional manifestation or malformation; or patient with genetically proven Kallmann syndrome and mirror movements.
* No contraindication for MRI or TMS study

Exclusion Criteria:

* inability to provide an informed consent
* Simultaneous participation in another clinical trial
* Treatment that modulate cortical excitability (for the TMS part of the study only)

Primary outcomes:
measure: - To unravel the pathophysiology of congenital mirror movements - To identify a locus and candidate genes associated with CMM
timeFrame: 08/2011
Secondary outcomes:
measure: - To study patients with Kallmann syndrome and associated MM based on the same methods and hypothesis
timeFrame: 08/2011
Other outcomes:
Locations:
city: Paris
country: France
facility: Fédération des Maladies du Système Nerveux, Hôpital Pitié Salpétrière
Study officials:
affiliation: Institut National de la Santé Et de la Recherche Médicale, France
name: Emmanuel ROZE, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06880861: Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
Official title: Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm
Keywords: cancer
adolescent
young adult
cognition
memory
exercise
physical activity
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2025-03-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with primary diagnosis of cancer when 15-39 years old.

Brief summary: This study evaluates relationships among physical activity, thinking, and memory after cancer treatment in survivors of adolescent and young adult cancers.


Eligibility criteria: Inclusion Criteria:

* Adults (aged 18+ years)
* Primary diagnosis of cancer when 15-39 years-old
* Access to a desktop computer or laptop with reliable internet access
* No gross motor impairments that prohibit ambulation
* Willing to complete study requirements
* English speaking

Exclusion Criteria:

* Diagnosed with nonmelanoma skin cancer only
* Not diagnosed with cancer in adolescent and young adult (AYA) age range of 15-39 years
* Scheduled travel during the study period that is not indicative of individual's normal schedule

Primary outcomes:
measure: Cognitive performance on Stroop task
timeFrame: Up to 4 weeks
Secondary outcomes:
measure: Cognitive performance on Visual Memory Test
timeFrame: 2 weeks
measure: Cognitive performance on Verbal Memory Test
timeFrame: 2 weeks
measure: Cognitive performance on Symbol Digit Coding Test
timeFrame: 2 weeks
measure: Cognitive performance on Shifting Attention Test
timeFrame: 2 weeks
measure: Cognitive performance on Continuous Performance Test
timeFrame: Up to 4 weeks
measure: Cognitive performance on Reasoning Test
timeFrame: 2 weeks
measure: Cognitive performance on Four Part Continuous Performance Test
timeFrame: 2 weeks
measure: Self-reported cognition - FACT-COG
timeFrame: 2 weeks
measure: Average weekly minutes of physical activity
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
Study officials:
affiliation: Mayo Clinic
name: Diane K. Ehlers, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02720861: Prevalence of Genetic Polymporphism on RNF213 rs112735431 Gene in Non-cardioemboli Ischemic Cerebrovascular Disease
Official title: Prevalence of Genetic Polymporphism on RNF213 rs112735431 Gene in Non-cardioemboli Ischemic Cerebrovascular Disease: A Cross-sectional Study in Thai Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ischemic Stroke
Keywords: RNF213 rs112735431 Gene
Acute Non-embolic ischemic stroke
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2016-03-28
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Acute ischemic stroke patients of Chulalongkorn hospital

Brief summary: To explore the prevalence of genetic polymorphism on RNF213 rs112735431 gene in non-cardioembolic ischemic cerebrovascular disease in Thai patients.

Detailed description: This is an cross-sectional observational study in Chulalongkorn hospital, to determine the prevalence of genetic polymorphism on RNF213 rs112735431 gene in non-cardioembolic ischemic cerebrovascular disease. Patients who are potentially eligible for study participation will be identified through a chart review of patients who were admitted in Chulalongkorn Hospital for acute ischemic stroke treatment.

Eligibility criteria: Inclusion Criteria:

* Nationality in Thailand
* Age equal or more than 18 years
* Clinical and imaging diagnosis of acute ischemic stroke
* Patient consent to participate in the research

Exclusion Criteria:

* High risk for cardioembolic stroke by TOAST classification
* Contraindication for venipuncture
* Pregnancy or breast feeding patient
* History of head and neck radiation
* Down's syndrome
* Marfan syndrome
* Autoimmune disease such as SLE
* Ongoing malignancy or remission of malignancy less than 1year

Primary outcomes:
measure: Number of Participants With RNF213 rs112735431 Gene polymorphism
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Suporn Travanichakul
Study officials:
affiliation: Chulalongkorn University
name: Suporn Travanichakul, MD
role: PRINCIPAL_INVESTIGATOR
References: